Tumor-targeted nanotherapeutics

Overcoming treatment barriers for glioblastoma

Aniket S. Wadajkar, Jimena G. Dancy, David S. Hersh, Pavlos Anastasiadis, Nhan Tran, Graeme F. Woodworth, Jeffrey A. Winkles, Anthony J. Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, αvβ3 integrin, glucose transporter(s), glial fibrillary acidic protein, connexin 43, epidermal growth factor receptor (EGFR), EGFR variant III, interleukin-13 receptor α chain variant 2, and fibroblast growth factor-inducible factor 14. However, most targeted therapeutic formulations have yet to demonstrate improved efficacy related to disease progression or survival. Potential limitations to current targeted nanotherapeutics include: (1) adhesive interactions with nontarget structures, (2) low density or prevalence of the target, (3) lack of target specificity, and (4) genetic instability resulting in alterations of either the target itself or its expression level in response to treatment. In this review, we address these potential limitations in the context of the key GBM targets with the goal of advancing the understanding and development of targeted nanotherapeutics for GBM. For further resources related to this article, please visit the WIREs website.

Original languageEnglish (US)
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
DOIs
StateAccepted/In press - 2016

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
Tumors
Interleukin-13 Receptors
Proteins
Connexin 43
Transferrin Receptors
Pharmacokinetics
Facilitative Glucose Transport Proteins
LDL Receptors
Glial Fibrillary Acidic Protein
Neurology
Fibroblast Growth Factor 2
Glycosaminoglycans
Drug delivery
Integrins
Neurons
Toxicity
Websites
Lipoproteins

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Bioengineering
  • Biomedical Engineering

Cite this

Tumor-targeted nanotherapeutics : Overcoming treatment barriers for glioblastoma. / Wadajkar, Aniket S.; Dancy, Jimena G.; Hersh, David S.; Anastasiadis, Pavlos; Tran, Nhan; Woodworth, Graeme F.; Winkles, Jeffrey A.; Kim, Anthony J.

In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016.

Research output: Contribution to journalArticle

Wadajkar, Aniket S. ; Dancy, Jimena G. ; Hersh, David S. ; Anastasiadis, Pavlos ; Tran, Nhan ; Woodworth, Graeme F. ; Winkles, Jeffrey A. ; Kim, Anthony J. / Tumor-targeted nanotherapeutics : Overcoming treatment barriers for glioblastoma. In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2016.
@article{62b707778cbb44f0ad6bce4ecdb103a9,
title = "Tumor-targeted nanotherapeutics: Overcoming treatment barriers for glioblastoma",
abstract = "Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, αvβ3 integrin, glucose transporter(s), glial fibrillary acidic protein, connexin 43, epidermal growth factor receptor (EGFR), EGFR variant III, interleukin-13 receptor α chain variant 2, and fibroblast growth factor-inducible factor 14. However, most targeted therapeutic formulations have yet to demonstrate improved efficacy related to disease progression or survival. Potential limitations to current targeted nanotherapeutics include: (1) adhesive interactions with nontarget structures, (2) low density or prevalence of the target, (3) lack of target specificity, and (4) genetic instability resulting in alterations of either the target itself or its expression level in response to treatment. In this review, we address these potential limitations in the context of the key GBM targets with the goal of advancing the understanding and development of targeted nanotherapeutics for GBM. For further resources related to this article, please visit the WIREs website.",
author = "Wadajkar, {Aniket S.} and Dancy, {Jimena G.} and Hersh, {David S.} and Pavlos Anastasiadis and Nhan Tran and Woodworth, {Graeme F.} and Winkles, {Jeffrey A.} and Kim, {Anthony J.}",
year = "2016",
doi = "10.1002/wnan.1439",
language = "English (US)",
journal = "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology",
issn = "1939-0041",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Tumor-targeted nanotherapeutics

T2 - Overcoming treatment barriers for glioblastoma

AU - Wadajkar, Aniket S.

AU - Dancy, Jimena G.

AU - Hersh, David S.

AU - Anastasiadis, Pavlos

AU - Tran, Nhan

AU - Woodworth, Graeme F.

AU - Winkles, Jeffrey A.

AU - Kim, Anthony J.

PY - 2016

Y1 - 2016

N2 - Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, αvβ3 integrin, glucose transporter(s), glial fibrillary acidic protein, connexin 43, epidermal growth factor receptor (EGFR), EGFR variant III, interleukin-13 receptor α chain variant 2, and fibroblast growth factor-inducible factor 14. However, most targeted therapeutic formulations have yet to demonstrate improved efficacy related to disease progression or survival. Potential limitations to current targeted nanotherapeutics include: (1) adhesive interactions with nontarget structures, (2) low density or prevalence of the target, (3) lack of target specificity, and (4) genetic instability resulting in alterations of either the target itself or its expression level in response to treatment. In this review, we address these potential limitations in the context of the key GBM targets with the goal of advancing the understanding and development of targeted nanotherapeutics for GBM. For further resources related to this article, please visit the WIREs website.

AB - Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, αvβ3 integrin, glucose transporter(s), glial fibrillary acidic protein, connexin 43, epidermal growth factor receptor (EGFR), EGFR variant III, interleukin-13 receptor α chain variant 2, and fibroblast growth factor-inducible factor 14. However, most targeted therapeutic formulations have yet to demonstrate improved efficacy related to disease progression or survival. Potential limitations to current targeted nanotherapeutics include: (1) adhesive interactions with nontarget structures, (2) low density or prevalence of the target, (3) lack of target specificity, and (4) genetic instability resulting in alterations of either the target itself or its expression level in response to treatment. In this review, we address these potential limitations in the context of the key GBM targets with the goal of advancing the understanding and development of targeted nanotherapeutics for GBM. For further resources related to this article, please visit the WIREs website.

UR - http://www.scopus.com/inward/record.url?scp=84996483728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996483728&partnerID=8YFLogxK

U2 - 10.1002/wnan.1439

DO - 10.1002/wnan.1439

M3 - Article

JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

SN - 1939-0041

ER -